Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 158 Lymphoma 156 Precursor Cell Lymphoblastic Leukemia-Lymphoma 130 Lymphoma, Non-Hodgkin 120 Leukemia 119 Leukemia, Lymphocytic, Chronic, B-Cell 116 Multiple Myeloma 115 Lymphoma, Large B-Cell, Diffuse 100 Leukemia, Myeloid, Acute 97 Hodgkin Disease 82 Myelodysplastic Syndromes 78 Lymphoma, Follicular 74 Lymphoma, Mantle-Cell 72 Burkitt Lymphoma 66 Lymphoma, B-Cell, Marginal Zone 52 Melanoma 49 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 48 Neoplasms 45 Recurrence 38 Hematologic Neoplasms 34 Lymphoma, Large-Cell, Immunoblastic 33 Myeloproliferative Disorders 31 Congenital Abnormalities 31 Waldenstrom Macroglobulinemia 30 Neoplasms, Plasma Cell 30 Leukemia, Myelomonocytic, Chronic 30 Lymphoma, B-Cell 29 Primary Myelofibrosis 27 Lymphoma, Large-Cell, Anaplastic 27 Leukemia, Myeloid, Accelerated Phase 26

Interventions

Carboplatin 42 Etoposide 37 Cisplatin 23 Topotecan 22 Nivolumab 17 pembrolizumab 12 atezolizumab 12 Ipilimumab 10 Paclitaxel 9 durvalumab 8 Irinotecan 8 Radiosurgery 6 Pemetrexed 6 rovalpituzumab tesirine 5 Magnetic Resonance Spectroscopy 5 trioctyl phosphine oxide 4 trilaciclib 4 etoposide phosphate 4 berzosertib 4 Sunitinib 4 Specimen Handling 4 Platinum 4 PM 01183 4 Dexamethasone 4 veliparib 3 tremelimumab 3 olaparib 3 carfilzomib 3 cabozantinib 3 Temozolomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Small Cell Lung Carcinoma × Cyclophosphamide × Clear all

NCT02566993 2021-10-28

ATLANTIS

PharmaMar

Phase 3 Completed

613 enrolled 46 charts

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡